Walk into a biostatistics group at a pharmaceutical company or a contract research organization and Python is often nowhere on the analysis side. R runs the survival curves, the mixed-effects models, and increasingly the tables that go into an FDA submission. This is not institutional nostalgia. It is a defensible technical choice, and the reasons hold up once you look at what the two languages actually do differently for statistical work, not general-purpose programming.
R was built in 1993 at the University of Auckland by Ross Ihaka and Robert Gentleman as a free, open-source reimplementation of S, the statistical language John Chambers had built at Bell Labs and that AT&T kept commercial. From day one, R treated the statistician as the primary user rather than the programmer. Vectors are the default data type. A linear model is a one-line formula. Plotting is a language primitive, not a bolted-on library. Python was never designed around that priority, and thirty years later the gap still shows up in exactly the places biostatistics lives: survival analysis, mixed models, and regulatory-grade reproducibility.
The Formula Syntax Is Doing Real Work
R’s model-fitting functions take a formula object: lm(response ~ predictor1 + predictor2, data = df). That tilde-based syntax is not cosmetic. It is a domain-specific language for specifying statistical models, and it lets a biostatistician write down interaction terms, random-effects grouping structures, and stratification variables directly in the notation a statistics textbook already uses. Python’s equivalents, whether through statsmodels or scikit-learn, require constructing design matrices more explicitly or leaning on formula-parsing libraries bolted on after the fact. For a one-off regression the difference is cosmetic. For a Phase III protocol with a dozen covariates, interaction terms, and a stratified randomization scheme, the formula syntax is the difference between a model specification a statistical reviewer can read at a glance and one they have to reverse-engineer from code.
The Survival Package Is Not a Library. It Is Infrastructure.
The clearest technical case for R sits inside a single package. R’s survival package, maintained by Terry Therneau, traces back to the S-Plus era in the late 1980s and implements the Cox proportional hazards model, competing risks analysis, time-dependent covariates, and censoring handling with a level of statistical depth that has been tested against real trial data for more than three decades. The companion coxme package extends this to mixed-effects Cox models, fitting random effects like site or center directly into a survival model, a requirement in almost any multi-site clinical trial.
Python’s rough equivalent, the lifelines package, is a genuinely good library built with modern software engineering practice in mind. It is also, by its own comparisons, narrower: fewer censoring mechanisms handled natively, thinner support for frailty models, and a shorter track record inside regulated submissions. This is not a knock on lifelines. It reflects a real difference in how the two ecosystems grew. R’s statistical packages accumulated three decades of methodological depth from working statisticians publishing their own methods as R packages first. Python’s data science ecosystem grew out of general-purpose scientific computing and machine learning, where survival analysis was one specialty among many rather than the center of gravity.
Academic Publication Still Runs Through R First
When a new statistical method gets published, the reference implementation is disproportionately an R package on CRAN, the Comprehensive R Archive Network. CRAN enforces a mandatory check process: every submitted package must pass automated tests, build its documentation cleanly, and declare its dependencies precisely, or it does not get listed. That is a low bar compared to a full regulatory qualification process, but it is a meaningfully higher bar than an arbitrary GitHub repository, and it means a biostatistician searching for, say, a Bayesian survival model with spatial random effects is more likely to find a maintained, documented CRAN package than an equivalent Python implementation.
Genomics and computational biology run through a parallel R ecosystem entirely: Bioconductor, a curated repository separate from CRAN with its own review process specifically for biological data structures and workflows. The packages behind differential gene expression analysis, sequence alignment postprocessing, and single-cell RNA-seq normalization overwhelmingly live in Bioconductor rather than in Python’s more general scientific stack, which is part of why R persists in the same labs producing work like protein language models even as the modeling itself increasingly happens in Python. The statistics downstream of the model, deciding whether an observed effect is real, still runs through R more often than not.
Why the FDA Angle Actually Matters
SAS remains the dominant language for compliance-driven regulatory work, and that is unlikely to change soon. It has decades of validated deployment inside pharmaceutical statistical programming groups, and switching a submission pipeline off SAS carries real institutional cost. But the R Consortium’s R Submissions Working Group has run five pilot submissions to the FDA between 2021 and 2024 using R-based statistical packages, establishing a real precedent that regulators will accept R-generated analysis when it meets the same documentation and reproducibility bar SAS submissions already clear.
That precedent matters because of where R is already winning inside pharma even without full submission authority. Early-phase exploratory analysis rewards flexibility over standardization. Real-world evidence studies pulling from electronic health records and patient registries generate messy data that R’s tooling handles more naturally. And increasingly R generates the tables, listings, and figures that support a submission even when the primary analysis still runs in SAS. The open-source ecosystem built around CDISC data standards for this work, collectively called the pharmaverse, provides validated R packages aligned to the SDTM and ADaM data models that regulatory submissions require. A typical Phase III trial needs 200 to 500 of these tables, listings, and figures, and pharmaverse tooling is increasingly what generates them.
The pharmaverse itself did not start as a vendor pitch. It began as a shared initiative among statisticians at GSK, Roche, Atorus, and Janssen to stop rebuilding the same clinical reporting packages inside every company’s walls, and by 2021 the results were already public: Merck released r2rtf, Atorus released pharmaRTF and Tplyr, Roche released rtables. Roche has since described its own move to an R-based primary backbone for clinical reporting as a multi-year internal project, not a pilot, and presented what the company called its first end-to-end R-based FDA submission at the 2024 R/Pharma conference. Package-level collaborations now span Roche, Novartis, GSK, Pfizer, Amgen, Bristol Myers Squibb, and Janssen, each contributing to shared, CDISC-aligned tooling rather than each maintaining a private equivalent. The COVID-19 RECOVERY Trial, one of the largest randomized clinical trials run during the pandemic, used R for its statistical analysis and reporting, demonstrating the language at genuine regulatory-grade scale under real time pressure rather than as an academic side tool, the same kind of real-world stress test this site covered when outbreak surveillance systems had to move from research prototypes into systems regulators and public health agencies actually rely on.
Where This Argument Runs Out
None of this makes R the better general-purpose choice, and a biostatistician who only knows R is increasingly at a disadvantage outside pure statistics. R’s package quality outside the statistical core is inconsistent in a way Python’s more centralized scientific stack is not. CRAN’s check process verifies a package builds and its examples run. It does not verify the underlying statistical method is correctly implemented, and a biostatistics team has to know independently which packages carry a track record of validation in regulated use and which are a single academic’s weekend project.
R’s deployment story is also genuinely behind Python’s for anything beyond a standalone analysis. It is single-threaded by default, its package installation and environment management have historically been rougher than Python’s virtual environments and now-standard tools like uv, and integrating an R analysis into a larger production system, an application backend, a live dashboard serving hundreds of concurrent users, a machine learning pipeline feeding a deployed model, is friction Python does not have. Engineers who move between the two ecosystems consistently describe R’s packaging and deployment model as the weakest part of the language, and that frustration is legitimate. It is also mostly irrelevant to the specific job of producing a validated Cox model for a clinical study report, which is the job R was built for and where thirty years of accumulated statistical tooling still shows.
The honest framing, and the one that actually helps a working practitioner decide, is not R versus Python as a global contest. It is: Python is the default for general data science, machine learning pipelines, and production software, and R remains the safer, more audit-friendly, statistically deeper choice specifically for regulated biostatistics, survival analysis, and mixed-effects modeling. Those are different jobs, and choosing the tool the job was built for beats choosing the tool with more general momentum. A biostatistics group that mandates one language for every task, in either direction, is optimizing for consistency over the quality of the actual analysis.
What a Practitioner Should Actually Do
For a biostatistician working inside a regulated pipeline today, the practical takeaway is not to pick a side. It is to know which of the two languages a specific task calls for. Exploratory work on messy real-world evidence data, complex survival models with frailty terms, or anything headed toward FDA-facing tables and listings has a real, current advantage running through R and the pharmaverse ecosystem built around it. General data engineering, machine learning integration, and anything that needs to run inside a larger production system leans Python, and increasingly a single team runs both, using R where the statistical depth pays for itself and Python where the engineering ecosystem does.
What Happens Next
The R Consortium’s submissions pilot program is continuing, and each additional accepted submission lowers the institutional risk of the next pharmaceutical company trying the same path. The pharmaverse ecosystem is still actively expanding its coverage of CDISC-aligned validated packages, which is the piece that determines how much of a submission pipeline can move off SAS without a company building its own internal tooling from scratch. Python’s statistical libraries are also improving, and the gap in survival analysis and mixed-effects modeling specifically is narrower than it was five years ago. Whether that gap closes further depends less on which language is more popular and more on whether Python’s ecosystem attracts the kind of decades-long methodological investment that built R’s survival package in the first place. That is a slower process than a popularity ranking suggests, and it is the actual variable worth watching instead of headline language rankings that measure job postings rather than statistical depth.
Leave a Reply